



MEDICAL TIPS

DIABIZ Tablets

Issue XI, No.43, 2023

Dapagliflozin or Saxagliptin in Pediatric Type 2 Diabetes

Shehadeh N, et al. NEJM. 2023.

- Despite the growing global burden of type 2 diabetes (T2DM) among children and adolescents, the treatment options available are currently limited.
- This was a randomized trial evaluating the efficacy and safety of Dapagliflozin (5 mg, n=81) in children and adolescents (age 10-17 years) with uncontrolled T2DM receiving Metformin, insulin, or both compared to Saxagliptin (2.5 mg, n=88) and placebo (n=76).
- At week 26, mean change in glycosylated hemoglobin (HbA1c) was -0.62% for Dapagliflozin compared to 0.41% for the placebo.
- The difference vs. placebo in HbA1c was -1.03 % ($p<0.001$) for Dapagliflozin and -0.44% ($p=0.078$) for Saxagliptin.

Dapagliflozin showed significant improvement in HbA1c and may be an important treatment consideration in children and adolescents with T2DM.



